bell
The current prices are delayed by 15 mins, login to check live prices.
Supriya Lifescience Ltd share price logo

Supriya Lifescience Ltd

(SUPRIYA)

₹706.75▲0.6%

as on 04:01PM, 24 Dec 2024

Overview
News
Financials
Q2 2024 Results
Technicals

Supriya Lifescience Ltd Analyst Rating

based on 1 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 1 analysts offering long term price targets for Supriya Lifescience Ltd. An average target of ₹644

Source: S&P Global Market Intelligence

Supriya Lifescience Ltd Share analysis

Supriya Lifescience Ltd price forecast by 1 analysts

Downside of-8.88%

High

₹644

Target

₹644.00

Low

₹644

Supriya Lifescience Ltd target price ₹644, a slight downside of -8.88% compared to current price of ₹706.75. According to 1 analysts rating.

Source: S&P Global Market Intelligence

Supriya Lifescience Ltd Performance

  • Day's Low

    Day's High

    ₹705.05
    Day's Price Range
    ₹720.3

  • 52 Week's Low

    52 Week's High

    ₹270.15
    52-Week Price Range
    ₹835.2
1 Month Return-10.9 %
3 Month Return+ 17.98 %
1 Year Return+ 122.91 %
Previous Close₹711.05
Open₹715.00
Volume1.34L
Upper Circuit-
Lower Circuit-
Market Cap₹5,688.12Cr

Supriya Lifescience Ltd Key Statistics

P/E Ratio0
PEG Ratio0
Market Cap₹5,688.12 Cr
P/B Ratio3.27
EPS0
Dividend Yield0
SectorPharmaceuticals
ROE15.73

Supriya Lifescience Ltd Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Supriya Lifescience Ltd
Supriya Lifescience Ltd
BUY₹5,688.12 Cr16.16%0.50NANA
Wanbury Ltd
Wanbury Ltd
NA₹887.00 Cr264.92%0.91₹55 Cr₹575 Cr
Themis Medicare Ltd
Themis Medicare Ltd
NA₹2,407.31 Cr159.02%0.62₹43 Cr₹381 Cr
Kwality Pharmaceuticals Ltd
Kwality Pharmaceuticals Ltd
NA₹930.38 Cr681.88%0.65₹23 Cr₹307 Cr
Kilitch Drugs (India) Ltd
Kilitch Drugs (India) Ltd
NA₹519.70 Cr31.31%0.56₹13 Cr₹154 Cr
See all

Supriya Lifescience Ltd Mutual Fund Holdings

About Supriya Lifescience Ltd

Supriya Lifescience Limited is an Indian manufacturing company and supplier of active pharmaceutical ingredients (APIs). As of 31 March 2021, the company has offered 39 APIs with a focus on therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics and anti-allergies. The company has consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India - 4555 and 6570 units, respectively - between Fiscal 2017 and 2020. Supriya Lifescience has sought approval for its products from international regulatory authorities including the USFDA, EUGMP and EDQM, and is supported by a modern manufacturing facility. Two new clean rooms are set to be powered up in the first quarter of Fiscal 2022. Over the years, the company has issued 3002400, 1626302, 9757804 Equity shares and increased its face value from Rs 10 to Rs 2 per share. In December 2021, Supriya Lifescience Limited conducted a Rs 700 crores public issue and the allotted shares were listed on BSE Ltd and NSE.

Share Price: ₹706.75 per share as on 24 Dec, 2024 04:01 PM
Market Capitalisation: ₹5,688.12Cr as of today
Listing date: 28 Dec, 2021
Chairperson Name: Satish Waman Wagh
OrganisationSupriya Lifescience Ltd
Headquarters
IndustryPharmaceuticals
E-voting on sharesClick here to vote

Key events for Supriya Lifescience Ltd

  • Supriya Lifescience Expands Capacity and Reports Strong Growth - 18 Dec, 2024

    Supriya Lifescience inaugurated a new API production facility, boosting capacity by over 55%. The company reported strong Q2 FY25 results, with significant revenue and profit growth, leading to a surge in stock price.

  • Supriya Lifescience Expands API Production Capacity - 17 Dec, 2024

    Supriya Lifescience inaugurated its new Module E API production block at Lote Parshuram, investing ₹125 crore and increasing capacity from 597 KLPD to 932 KLPD, a growth of over 55%. This expansion supports the company's strategic focus on R&D and innovative products.

  • Supriya Lifescience Gains ANVISA Approval for Drug - 09 Dec, 2024

    Supriya Lifescience Ltd has secured ANVISA approval for Esketamine Hydrochloride, becoming the first Indian company to do so. This milestone, along with a patent for a cost-effective atorvastatin synthesis, positions the company for growth in the LATAM market. Shares rose 1.16% following the announcement.

Insights on Supriya Lifescience Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, SUPRIYA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 4.95% to 6.03% in Sep 2024 quarter

  • imgPOSITIVE IMPACT

    MF Holding Up

    img

    Mutual Funds have increased holdings from 0.13% to 0.62% in Sep 2024 quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 68.30% of holdings in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Retail Holding Down

    img

    Retail Investor have decreased holdings from 21.27% to 20.23% in Sep 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, SUPRIYA stock has moved down by -10.9%

Supriya Lifescience Ltd Financials

Value in ₹ crore
Details2021202220232024
Total Assets₹445.76Cr (-)₹737.14Cr (↑65.37%)₹820.71Cr (↑11.34%)₹921.25Cr (↑12.25%)
Total Liabilities₹177.17Cr (-)₹121.45Cr (↓31.45%)₹121.25Cr (↓0.16%)₹105.88Cr (↓12.68%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹116.67Cr (-)₹75.89Cr (↓34.95%)₹48.80Cr (↓35.70%)₹63.61Cr (↑30.35%)₹113.31Cr (↑78.13%)

Index Inclusions

BSE Healthcare

₹44,092.04

0.03 (▲13.51%)

BSE Small-Cap

₹55,023.17

0.37 (▲205.26%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Supriya Lifescience Ltd Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
68.3%
0.00
Foreign Institutions
6.03%
21.78
Mutual Funds
0.62%
369.71
Retail Investors
20.23%
-4.91
Others
4.83%
-9.71

Supriya Lifescience Ltd Key Indicators

Details20202021202220232024
Return On Equity %60.4159.1834.3413.6715.73

Supriya Lifescience Ltd Earnings and Dividends

  • Supriya Lifescience Ltd Earnings Results

    Supriya Lifescience Ltd’s net profit jumped 93.26% since last year same period to ₹46.15Cr in the Q2 2024-2025. On a quarterly growth basis, Supriya Lifescience Ltd has generated 3.38% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Supriya Lifescience Ltd Dividends May,2024

    In the quarter ending March 2024, Supriya Lifescience Ltd has declared dividend of ₹0.80 - translating a dividend yield of 0.11%.

    Read More about Dividends

Supriya Lifescience Ltd Technicals Summary

Bearish

Neutral

Bullish

Bullish

Supriya Lifescience Ltd is currently in a Bullish trading position according to technical analysis indicators.

More on Technical Analysis

FAQs on Supriya Lifescience Ltd

  • Get a PAN card.
  • Open a Demat account.
  • Open a Trading account.
  • Link your Demat account to your Trading account.
  • Fund your Trading account.
  • Place an order to buy Supriya Lifescience Ltd shares.

Supriya Lifescience Ltd (SUPRIYA) share price today is ₹706.75

Supriya Lifescience Ltd is listed on NSE

Supriya Lifescience Ltd is listed on BSE

  • Today’s highest price of Supriya Lifescience Ltd is ₹720.3.
  • Today’s lowest price of Supriya Lifescience Ltd is ₹705.05.

Today’s traded volume of Supriya Lifescience Ltd(SUPRIYA) is 1.34L.

Today’s market capitalisation of Supriya Lifescience Ltd(SUPRIYA) is ₹5688.12Cr.

Supriya Lifescience Ltd(SUPRIYAPrice
52 Week High
₹835.2
52 Week Low
₹270.15

Supriya Lifescience Ltd(SUPRIYA) share price is ₹706.75. It is down -15.38% from its 52 Week High price of ₹835.2

Supriya Lifescience Ltd(SUPRIYA) share price is ₹706.75. It is up 161.61% from its 52 Week Low price of ₹270.15

Supriya Lifescience Ltd(SUPRIYAReturns
1 Day Returns
-4.3%
1 Month Returns
-10.9%
3 Month Returns
17.98%
1 Year Returns
122.91%